|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400094517 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-24 11:03:51 |
|
注册时间: Date of Registration: |
2024-12-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
早孕期血糖代谢异常孕妇进行生活方式干预的有效性: EAGM随机对照试验 |
|
Public title: |
Effectiveness of a lifestyle intervention for pregnant women with abnormal glucose metabolism in early pregnancy: EAGM randomized controlled trial. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
早孕期血糖代谢异常孕妇进行生活方式干预的有效性: EAGM随机对照试验 |
|
Scientific title: |
Effectiveness of a lifestyle intervention for pregnant women with abnormal glucose metabolism in early pregnancy: EAGM randomized controlled trial. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
沈丽霞 |
研究负责人: |
陈海天 |
|
Applicant: |
Lixia Shen |
Study leader: |
Haitian Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 159 2037 8166 |
研究负责人电话: Study leader's telephone: |
+86 137 6333 2296 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shenlx06@163.com |
研究负责人电子邮件: Study leader's E-mail: |
chhait@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省广州市中山二路58号,中山大学附属第一医院,妇产科 |
研究负责人通讯地址: |
中国广东省广州市中山二路58号,中山大学附属第一医院,妇产科 |
|
Applicant address: |
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Number 58 Zhongshan Second Road, Guangzhou 510080, China. |
Study leader's address: |
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Number 58 Zhongshan Second Road, Guangzhou 510080, China. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Sun Yat-sen University |
||
|
研究负责人所在单位: |
中山大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审临[2024]645号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第一医院临床科研和实验动物伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research and Laboratory Animal Ethics Committee, The First Affiliated Hospital of Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-15 00:00:00 |
||
|
伦理委员会联系人: |
陈湛勇 |
||
|
Contact Name of the ethic committee: |
Zhanyong Chen |
||
|
伦理委员会联系地址: |
广州市中山二路58号,中山大学附属第一医院临床科研和实验动物伦理委员会 |
||
|
Contact Address of the ethic committee: |
Clinical Research and Laboratory Animal Ethics Committee, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8733 4871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广东省,广州市中山二路58号,中山大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
The First Affiliated Hospital of Sun Yat-sen University, Number 58 Zhongshan Second Road, Guangzhou 510080, China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中山一院专科能力提升计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
Abiility Enhancement Plan, FAH-SYSU |
||||||||||||||||||||||
|
Target disease: |
Hyperglycemia in Pregnancy |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探究EAGM孕妇通过常规产检结合生活方式干预,与仅常规产检相比,是否能有效预防大于胎龄儿和早产发生。 |
||||||||||||||||||||||
|
Objectives of Study: |
To assess whether the application of lifestyle intervention, in addition to routine regular prenatal care, is superior to routine regular prenatal care without lifestyle intervention for preventing GDM in pregnant women with EAGM. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.超过18岁 2.签署知情同意书 3.单胎活胎 4.14周前发现血糖代谢异常,定义为FPG 5.1-6.9mmol/L和/或HbA1c 5.7%-6.4% |
||||||||||||||||||||||
|
Inclusion criteria |
1.Over 18 years of age. 2.Able to provide informed consent. 3.Singleton pregnancies. 4.An abnormal glucose metabolism determined by a blood test performed prior to 14 weeks, defined as FPG 5.1-6.9mmol/L and/or HbA1c 5.7-6.4%. |
||||||||||||||||||||||
|
排除标准: |
1.孕前糖尿病(孕前诊断为糖尿病,或首次产检时发现FPG≥7.0mmol/L或HbA1c≥6.5%) 2.因妊娠早期超声检查发现胎儿异常计划终止妊娠。 3.随机分组时正在使用已知会干扰糖代谢的药物(如皮质类固醇、抗精神病药物等)。 4.经试验监测小组的评估存在可能干扰试验进行的任何其他身体状况(如癌症、器官衰竭、癫痫、截瘫、残疾等严重疾病)或心理状况(如学习困难、严重精神疾病)等。 5.目前因妊娠剧吐导致脱水或需要住院治疗的孕妇;如果上述情况在妊娠14+6周前已治愈,并符合所有其他纳排标准,则可重新评估是否纳入本试验。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Pregestational diabetes (diagnosed as diabetes mellitus before pregnancy, or FPG≥7.0mmol/L, or HbA1c≥6.5% at the first prenatal visit), impaired fasting glucose or impaired glucose tolerance diagnosed before pregnancy. 2.Plan for termination of pregnancy due to fetal anomaly identified at the first trimester scan. 3.Use of medications known to interfere with glucose metabolism (e.g. corticosteroids, antipsychotic drugs) at the time of randomisation. 4.Any other physical (serious medical conditions such as cancer, organ failure, epilepsy, paraplegia, disability) or psychological condition (e.g. learning difficulties, serious mental illness) that is likely to interfere with the conduct of the trial according to evaluation by the trial monitoring group. 5.Women currently with hyperemesis gravidarum leading to dehydration or requiring hospitalization. If persisting vomiting resolves, the patient may be reassessed for inclusion in the trial up to and including 14+6 weeks of gestation, providing all other inclusion and exclusion criteria are met. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2027-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-01-01 00:00:00 至 To 2027-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机分组将通过中山大学附属第一医院临床研究中心(FAH-SYSU Clinical Trials Unit, GCTU)的安全在线随机系统进行。根据计算机生成的随机序列,符合条件的受试者以1:1的比例随机分为干预组或对照组。通过分层区组随机化确保干预措施的分配均衡,分层因素如下: 1.孕前体重指数≥24.0kg/m2(是或否) 2.孕妇年龄≥35岁(是或否) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomisation will be provided by a secure online randomization system at the FAH-SYSU Clinical Trials Unit (GCTU). Eligible participants are randomized in a 1:1 ratio into the intervention or control group based on a computer-generated random sequence. Randomization is stratified by the following factors using permuted block randomisation to ensure a balance in the treatment allocation: 1.Body mass index before pregnancy ≥24.0kg/m2 (yes or no) 2.Maternal age ≥35 years old (yes or no) |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
开放 |
|
Blinding: |
Open label |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
向研究者联系索取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Please contact the researcher |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |